SCHEMBL10067306

SCHEMBL10067306

Cc1c(-c2nc3c4cccnc4c4ncccc4c3[nH]2)c2ccccc2n1CC(=O)N1CCC(C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
ATM Q13315 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 4/20 0.41
TP53 P04637 1/20 0.41
LMNA P02545 4/20 0.41
GLA P06280 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067277 0.91 LMNA (0.50) TSHRSMN1; SMN2NPSR1MAPTMEN1
SCHEMBL10067295 0.90 LMNA (0.49) TSHRNPSR1MAPTMEN1KMT2A
SCHEMBL10067281 0.90 LMNA (0.49) TSHRNPSR1MAPTMEN1KMT2A
SCHEMBL10067278 0.86 TSHR (0.47) TSHRSMN1; SMN2NPSR1MAPTCYP1A2
SCHEMBL10067293 0.82 ALDH1A1 (0.52) TSHRSMN1; SMN2MAPTKMT2APOLB
SCHEMBL10067353 0.76 NPSR1 (0.62) TSHRSMN1; SMN2NPSR1MAPTCYP1A2
SCHEMBL10067289 0.73 KDM4E (0.37) NPSR1MAPTCYP2C19ATMMEN1
SCHEMBL10067267 0.71 MAPT (0.46) TSHRMAPTTP53LMNAL3MBTL1
SCHEMBL10067310 0.71 KMT2A (0.48) NPSR1MAPTMEN1KMT2ATP53
SCHEMBL10067302 0.70 MAPT (0.48) TSHRMAPTPOLBTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 TSHR 3689/4885SMN1; SMN2 3833/4885NPSR1 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.